ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Owen Dempsey

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton May 26, 2021 7:48am

118 Views

Post# 33266178

RE:Owen Dempsey

I'm guessing B. I think June 1 could still be the date, but that presale prior to approval might have been ill-advised, and as you noted, now corrected.

Looking forward to another UP day for PMN/ARFXF! Hopefully we gets some more PRs circa 31 May.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market